Navigation Links
SEQUEL Trial Results for Qnexa® Published in AJCN Show 10% Sustained Weight Loss Over 2 Years
Date:12/8/2011

es Litigation Reform Act of 1995.  These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," predict," "opportunity" and "should," among others.  There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.  These factors include, but are not limited to, the response from the United States Food and Drug Administration, or FDA, to our resubmission of the New Drug Application, or NDA, for Qnexa for the treatment of obesity, including weight loss and maintenance of weight loss, recommended for obese patients (BMI >30 kg/m2), or overweight patients (BMI >27 kg/m2) with weight-related co-morbidities such as hypertension, type 2 diabetes, dyslipidemia, or central adiposity (abdominal obesity), with a contraindication that excludes the use of Qnexa by women of child-bearing potential; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy; the reliability of the electronic medical claims healthcare databases used in the FORTRESS study; the FDA's interpretation of and agreement with the information VIVUS submitted relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study (OB-305) and Sleep Apnea study (OB-204); that we may be required to conduct additional prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; our response to questions and requests for additional information including additional pre-clinical or clinical studies from the European Medicines Agency, or EMA, and the Committee for Medicinal Products for Human Use, or CHMP, of the Marketing Authorization Application, or MAA, for Qnexa; the results of external studies to assess the t
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Additional Analysis from Two-Year Sequel Study of QNEXA Featured at The 2011 Annual Scientific Meeting of The Obesity Society
2. Data From QNEXA Sequel Study Featured at the 47th EASD Annual Meeting
3. SequelMed EMR Version 8 Certified by Ohio Board of Pharmacy
4. Sequel Systems, Inc. Meaningful Use EHR Receives ONC-ATCB 2011/2012 Certification
5. Sequella and University of Maryland Restate Exclusive License for Jointly Owned Event Marker System Technology
6. Sequella Receives American Recovery and Reinvestment Funding Through the NIH
7. Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
8. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
9. TIs new MSP430™ microcontrollers enable more performance and higher precision in home automation, industrial and portable medical applications
10. GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market
11. GiiResearch.com: Insulin Pumps - Availability of Reimbursement and Favorable Clinical Trial Data to Drive Market Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Mettler-Toledo International Inc. (NYSE: MTD ) ... are the highlights: , Sales in local ... the prior year. Reported sales increased 5% which included ... per diluted share as reported (EPS) were $2.49, compared ... EPS was $2.57, an increase of 9% over the ...
(Date:7/24/2014)... Amgen (NASDAQ: AMGN ) today announced ... Tuesday, July 29, 2014, after the close of the U.S. ... call with the investment community at 2 p.m. PT. Participating ... Bradway , chairman and chief executive officer, and other members ... the conference call will be simultaneously broadcast over the Internet ...
(Date:7/24/2014)... , July 24, 2014 IGI Laboratories, Inc. ... based specialty generic pharmaceutical company, today announced it ... Board of Directors.  Mr. Finio has accepted a senior ... the terms of his acceptance of his new position, ... role as Director for IGI Laboratories, Inc.  The effective ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Amgen Announces Webcast of 2014 Second Quarter Financial Results 2IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... BEIJING, May 7, 2012 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. ... leading plasma-based biopharmaceutical companies in the People,s Republic of China, ... covering its first quarter 2012 results on May 9, 2012 ... p.m. in China on the same day. Hosting ...
... S. Weinstock and G. Scott Vezina of ... obtained a $78.5 million verdict on behalf of a child ... negligence. The child, now 3 years old, has severe spastic ... of an emergency cesarean section delivery. The case was tried, ...
Cached Medicine Technology:China Biologic Products to Host Earnings Conference Call on May 9, 2012 at 8:00 a.m. EDT (NY) 2$78.5 Million Jury Verdict In Philadelphia Birth Injury Case 2$78.5 Million Jury Verdict In Philadelphia Birth Injury Case 3
(Date:7/26/2014)... July 26, 2014 The European security ... at $1290 million in 2014, and it is expected ... of 6.16%. The report incorporates the factors that influence ... of growth rates and projected total expenditure. The report ... global markets. Apart from the general overview of the ...
(Date:7/26/2014)... The North America Cyber Security report ... North America with analysis and forecast of revenue. This ... in 2014 to $33.24 billion by 2019, at a ... through the TOC of the North America Cyber Security ... analysis provided. It also provides a glimpse of the ...
(Date:7/26/2014)... (PRWEB) July 26, 2014 The European Artificial ... in Europe with analysis and forecast of revenue. The artificial ... $3.5 billion in 2013 to around $5.4 billion by 2018, ... , Browse through the TOC of European artificial lift market ... also provides a glimpse of the segmentation in European Artificial ...
(Date:7/26/2014)... 2014 The European gas chromatography reagents report ... and forecast of revenue. The gas chromatography reagents market in ... is estimated to grow to around $445.5 million by 2018, ... , Browse through the TOC of the European gas chromatography ... provided. This report also provides a glimpse of the segmentation ...
(Date:7/26/2014)... 26, 2014 Recently, iFitDress.com, a popular ... women, has unveiled its new range of high quality ... on the brand new items; they are now provided ... , iFitDress.com is one of the leading suppliers in ... all the wholesale party dresses have flattering ...
Breaking Medicine News(10 mins):Health News:Europe Security and Surveillance Radar Market is Expected to Reach $1800 million in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Security and Surveillance Radar Market is Expected to Reach $1800 million in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Security and Surveillance Radar Market is Expected to Reach $1800 million in 2019 - New Report by MicroMarket Monitor 4Health News:Europe Security and Surveillance Radar Market is Expected to Reach $1800 million in 2019 - New Report by MicroMarket Monitor 5Health News:North America Cyber Security Market is Expected to Reach $33 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America Cyber Security Market is Expected to Reach $33 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America Cyber Security Market is Expected to Reach $33 billion in 2019 - New Report by MicroMarket Monitor 4Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 5Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 5Health News:High Quality Wholesale Party Dresses Online at iFitDress.com 2
... to patients with a history of growths in their colon ... believe that most colorectal cancer develop out of polyps, or ... ,However, the latest research, conducted in France, Denmark, Italy ... to grow in patients given this fibre supplementation. In 456 ...
... researchers, a new treatment has been effective for inoperable liver cancer. It ... and it is showing a 25 ... per cent success rate in either reducing tumour size or the ... treatment with advanced liver tumours, who cannot be treated by any other ...
... people who suffer from dementia benefit from music therapy. The ... music. The trials have found that the therapy is popular ... ,scientists at Imperial College London are planning to carry out ... therapy has long term benefits for dementia sufferers. If their ...
... supplements given to babies with low birth weight can ... often die from infectious diseases. The research involved 1,154 ... Delhi, India, most weighing 5 1/2 pounds or less. ... nine months. Fifteen of the 20 who died had ...
... India (MSI), the sole franchisee for US based Medicine Shoppe ... has dropped Chennai from list of its target for operations ... drew up plans to expand its franchisee operations from the ... current financial year, has decided to put on hold the ...
... heavy breakfast and a steaming cup of tea may increase a ... fried food each morning are at twice the risk of the ... reduce the incidence of cancer is to begin the day with ... of the oesophagus - the food pipe connecting the stomach with ...
Cached Medicine News:Health News:Cut down on fries 2
... Solo microplate incubator is an extremely ... a single microplate up to 50C. ... applications requiring higher temperatures up to ... offering low cost and high performance ...
... The iEMS Incubator/Shaker HT is ... the iEMS Incubator/Shaker HT is ... DNA hybridization and primer extension ... available as a one-cabinet model, ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Minimal M9CA Broth...
Medicine Products: